Launches oral and injectable formulations of Semaglutide - Torrent Pharmaceuticals Ltd

Code BSE: 500420 NSE:

Torrent Pharma launches oral and injectable formulations of Semaglutide Commenting on the launch, Amal Kelshikar, CEO – India Business, Torrent Pharma, said: “Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options available to healthcare professionals managing complex metabolic conditions at affordable prices. We are proud to be the first Indian company to offer this treatment across oral and injectable formulations, giving healthcare professionals a holistic choice for treating patients”